glisoxepide
Enable an agent to recognise glisoxepide, assess the identity and condition of a supplied material, and determine which handling or research actions its evidence supports.
Bundle → Layer → Finding → Questions Filled
6 bundles · 11 layers · 15 findings · 28 questions
Glisoxepide identity Establish what chemical the registry name and a supplied sample denote.
Molecular recognition
Compare chemical connectivity and composition with an identified reference.
Structure match
Require a structure-based identity decision supported by the applicable analytical evidence.
- Which reference structure defines glisoxepide, including the connectivity of its isoxazole and azepane-containing portions? definition
- Which orthogonal analytical results distinguish this sample from related sulfonylureas and plausible structural impurities? measurement
Identifier and form boundaries
Resolve external identifiers and the relationship between the parent substance and supplied forms.
Identifier reconciliation
Record only identifiers whose underlying substance identity has been checked.
- Which CAS, EC, PubChem and UNII records have been read and confirmed to describe the same glisoxepide structure? provenance
- Does the supplied name denote the parent substance, a documented alternative form or a product containing glisoxepide? boundary
Glisoxepide material quality Determine how much identified glisoxepide a batch contains and what accompanies it.
Assay and identity evidence
Connect batch acceptance to methods capable of identifying and quantifying glisoxepide.
Batch assay basis
Distinguish quantified content from area-normalised purity and document the reference standard.
- Is reported glisoxepide purity an absolute assay, a dry-basis result or chromatographic area percentage? measurement
- What establishes the identity, assigned content and traceability of the glisoxepide reference standard? provenance
Impurities and use grade
Evaluate non-glisoxepide material against the proposed use.
Quality disposition
Base acceptance on measured impurities and an explicit specification.
- Which related substances, residual solvents and water levels were measured, and which remain unidentified or unmeasured? measurement
- Does this batch meet the documented requirements for the intended glisoxepide experiment or material use? action
Glisoxepide physical state and preparation Characterise the supplied solid and the conditions under which it forms a usable solution.
Solid and thermal behaviour
Record observed solid form and measured thermal transitions without assuming a universal material state.
Solid form evidence
Tie phase and thermal observations to the tested glisoxepide sample.
- What diffraction or thermal evidence establishes this sample's crystallinity and any claimed polymorph, hydrate or solvate? measurement
- Does the reported thermal event represent melting, solvent loss or decomposition, and under which measurement conditions? measurement
Dissolution and solution persistence
Assess concentration, solvent conditions and changes after preparation or dilution.
Usable dissolved concentration
Require evidence that glisoxepide remains dissolved and chemically intact during use.
- What glisoxepide solubility was measured at the intended solvent composition, pH and temperature? measurement
- After dilution into the intended medium, what measurements exclude precipitation or significant chemical loss over the exposure period? measurement
- Which preparation and storage interval is supported by those measurements? action
Glisoxepide biological evidence Organise evidence for biological activity without converting class membership into compound-specific proof.
Activity and mechanism
Separate observed glucose-related effects from direct evidence of molecular interaction.
Compound-specific support
Require glisoxepide-specific experiments for mechanistic and potency claims.
- Which studies directly test glisoxepide effects on insulin release or glucose-related endpoints? provenance
- Which target or channel interactions were measured directly, and which are inferred from sulfonylurea class behaviour? boundary
Assay interpretability
Connect an activity result to chemical exposure and biological context.
Comparable exposure
Retain the conditions needed to decide whether glisoxepide results can be compared.
- What species, cell or tissue system, endpoint, exposure duration and concentration basis produced the reported result? measurement
- Were material identity, dissolved concentration, vehicle effects and relevant controls sufficient to attribute the result to glisoxepide? provenance
- Does the evidence support the proposed experiment, or require additional validation before use? action
Glisoxepide handling and status Determine applicable material controls and distinguish chemical identity from permission to use it.
Exposure and storage controls
Link handling decisions to documented hazards and stability for the actual material.
Supported material controls
Record evidence for precautions covering glisoxepide solids, solutions and waste.
- Which current safety document covers this glisoxepide material, and what evidence supports its GHS classification and any exposure limit? provenance
- What containment, storage and disposal controls follow from the documented hazards, solvent composition and stability evidence? action
Jurisdiction and intended use
Separate substance registration, research supply and medicinal-product authorisation.
Use status evidence
Attach each regulatory conclusion to its jurisdiction, date and regulated object.
- Which authoritative record establishes the status relevant to the proposed glisoxepide use in the named jurisdiction? provenance
- Does that record concern the chemical substance, a particular medicinal product or a supplier's research-use designation? boundary
- What additional evidence is required before the material can be assigned to the proposed use? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these check these first hold for the sense of glisoxepide this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these identifiers and schemes hold for the sense of glisoxepide this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these real-world use hold for the sense of glisoxepide this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these failure modes and hazards hold for the sense of glisoxepide this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of glisoxepide this model covers, and on what evidence? provenance
Classifiers Filled
- Family
- Thing Registry
- Category
- Physical world and living systems
- Entry kind
- thing
- Plane
- PHY
- Domain
- PHY.MAT
What it is Filled
Glisoxepide is a sulfonylurea antidiabetic drug that lowers blood glucose by stimulating insulin secretion from pancreatic beta cells.
In scope
- Molecular identity and reconciliation of substance identifiers
- Purity, grade, impurities and analytical evidence for supplied material
- Solid form, solution behaviour and stability under recorded conditions
- Glisoxepide-specific biological activity and limits of supporting evidence
- Chemical handling hazards and jurisdiction-specific substance status
Out of scope
- Finished medicines, their excipients, packaging and release specifications
- Patient diagnosis, prescribing, dose selection and treatment monitoring
- Manufacturing routes and production equipment
- The sulfonylurea class as a whole
- Separate models of metabolites, degradation products or other active ingredients
Why it exists Filled
Enable an agent to recognise glisoxepide, assess the identity and condition of a supplied material, and determine which handling or research actions its evidence supports.
Distinguishing features Filled
- Match the molecular structure to the glisoxepide reference record, PubChem CID 32778; a similar drug name or shared sulfonylurea class is insufficient. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Glisoxepide)
- Check the reference molecular formula C20H27N5O5S, while requiring structural evidence because formula alone cannot establish identity. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Glisoxepide)
- Check the connectivity of the isoxazole-containing substituent and azepane-containing sulfonylurea structure against the systematic identity associated with UNII H7SC0I332I. [FDA substance record](https://precision.fda.gov/uniisearch/srs/unii/h7sc0i332i)
- Distinguish the substance from a tablet, mixture or stock solution containing it by separately identifying the active chemical and the supplied composition.
- Treat antihyperglycemic sulfonylurea activity as supporting classification, not as a unique identity test. [NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/glisoxepide)
What robots and AI may and may not do Filled
Must not
- Recommend, dose or supply it to a person without a prescriber's decision.
- Advise skipping meals or combining it with alcohol while taking it.
- Assist in giving it to anyone without their knowledge.
Only with a human decision
- Any decision to start, stop or change diabetes treatment.
May
- Describe glisoxepide as a sulfonylurea used for type 2 diabetes where licensed.
- Explain hypoglycaemia warning signs in general terms.
Moral aspects Filled
- Low blood sugar can kill, and older people living alone are most at risk.
Who is affected
- People with type 2 diabetes
- Older people
- Carers
Owners Filled
Steward
The marketing authorisation holder where it is licensed; the prescriber answers for each use.
Master systems
- National medicines registers
Links to other meta-models Filled
parent
- Q11173 - registry parent class
What else AI and robots need to interact with it Filled
Identity and identifiers required Filled
- Vercy registry: vr.tr.glisoxepide
- Wikidata: Q5569932 (https://www.wikidata.org/wiki/Q5569932)
Direct properties required Filled
- Reference molecular identity: Registry vr.tr.glisoxepide linked to a verified molecular structure and external substance records
- Supplied chemical form: Parent substance, claimed salt, hydrate, solvate or mixture; verified or unresolved
- Assay and impurity profile: % mass fraction or explicitly stated analytical basis; impurity concentrations with method and detection limits
- Material grade: Supplier-declared grade with intended use and supporting specification; unverified when unsupported
- Solid-state identity: Observed phase, crystallinity and any demonstrated polymorph or solvate identity, with conditions
- Thermal behaviour: Melting or decomposition temperature in °C, with method; boiling point only if experimentally meaningful
- Solubility and ionisation: Solubility in mg/mL or mol/L at specified solvent, pH and temperature; pKa with method
- Stability under use conditions: Remaining assay %, impurity change and precipitation over time under recorded storage or incubation conditions
- Biological activity evidence: Glisoxepide-specific study, endpoint, biological system, concentration, exposure time and result
- Hazard and regulatory determination: Documented classification or unresolved status, with jurisdiction, source, revision date and material scope
Recognition required Filled
- Identity cannot be settled by sight; tablets must be confirmed by label and pharmacy records.
Capabilities and actions required Filled
- Reconcile a labelled glisoxepide sample with a reference molecular identity.
- Accept, quarantine or reject a batch against an explicit analytical specification.
- Assess whether a proposed solvent and concentration have adequate preparation and stability evidence.
- Compare glisoxepide activity results after checking sample quality and assay conditions.
- Determine which storage, handling and disposal instructions apply to the supplied material.
- Identify missing evidence before assigning a material to a proposed research or regulated use.
Hazards and failure modes required Filled
- Hypoglycaemia, sometimes prolonged and severe.
- Interactions with other drugs that raise its effect.
Standards and interfaces required Filled
- The Anatomical Therapeutic Chemical classification maintained by the World Health Organization Collaborating Centre for Drug Statistics Methodology classifies glisoxepide among sulfonylureas.
Context of use required Filled
- Glisoxepide is encountered in pharmaceutical literature and research concerning sulfonylurea medicines for type 2 diabetes.
- Supplied samples may be used for analytical identification or laboratory investigation when their identity, purity and intended use are documented.
Sources Filled
- Wikidata item Q5569932: glisoxepide - identity and sense of the item
- Wikipedia: Glisoxepide - general description of the item
Open questions
- Which CAS and EC identifiers are authoritatively linked to the reference glisoxepide structure, and are alternative chemical forms documented?
- Which solid forms, melting or decomposition behaviour, solubility values and pKa measurements have reliable experimental support?
- Which analytical specifications establish glisoxepide assay, relevant impurities and stability in solids and working solutions?
- Which primary studies establish glisoxepide-specific molecular mechanisms, potency and additional biological activities rather than class-based inference?
- What current jurisdiction-specific regulatory records, hazard classifications and occupational exposure limits apply to glisoxepide?
Machine files
Provenance
thing registry research (pass 2) · unreviewed
Built from: models/things/publications/thing-q5569932/spec.json